<a href="https://www.fiercebiotech.com/sponsored/signal-changes-everything-understanding-mrd-oncology-drug-development-0" hreflang="en">The signal that changes everything: understanding MRD in oncology drug development</a>
Is the cancer truly gone?
Fierce Biotech — page 2
29 articlesfiercebiotech.com ↗
Coverage, page 2
page 2 of 2
<a href="https://www.fiercebiotech.com/sponsored/moving-nams-progress-practice-building-foundation-broader-adoption" hreflang="en">Moving NAMs from Progress to Practice: Building the Foundation for Broader Adoption</a>
The future of NAMs depends on more than innovation. Learn how sourcing, standards and evidence can accelerate adoption.
<a href="https://www.fiercebiotech.com/medtech/jj-looking-offload-orthopedics-unit-20b-deal-apollo-bloomberg" hreflang="en">J&J looking to offload orthopedics unit in $20B deal to Apollo: Bloomberg</a>
Johnson & Johnson is nearing a $20 billion deal to sell off its unwanted hips-and-knees business DePuy Synthes to private equity firm Apollo Equity Management.
<a href="https://www.fiercebiotech.com/marketing/no-more-nordisk-novo-goes-it-alone-amid-rebranding-push" hreflang="en">No more Nordisk as Novo goes it alone amid rebranding push</a>
As Novo Nordisk continues its epic battle with Eli Lilly for market share in the increasingly competitive obesity and diabetes space, Novo is launching a major rebranding of its business, its logo and its name.
<a href="https://www.fiercebiotech.com/biotech/definium-lsd-drug-goes-3-3-another-pivotal-anxiety-trial-win" hreflang="en">Definium LSD drug goes 3 for 3 with another pivotal anxiety trial win</a>
Definium Therapeutics has scored a third straight phase 3 win for its LSD formula, with the psychedelic significantly alleviating anxiety symptoms and setting up an FDA filing later this year.
<a href="https://www.fiercebiotech.com/biotech/cellectis-cans-allogeneic-car-ts-hop-aboard-vivo-bandwagon" hreflang="en">Cellectis cans allogeneic CAR-Ts to hop aboard in vivo bandwagon</a>
Cellectis may have kicked off the year promising “huge momentum” in the allogeneic CAR-T space, but even the French biotech has been unable to resist the dominance of in vivo options.
<a href="https://www.fiercebiotech.com/biotech/roche-and-medilink-notch-phase-3-lung-cancer-win-trail-gsk-cross-trial-survival" hreflang="en">Roche, MediLink notch phase 3 lung cancer win but trail GSK on cross-trial survival</a>
MediLink has reported phase 3 results on a Roche-partnered antibody-drug conjugate. The small-cell lung cancer trial hit its primary endpoint, although the B7-H3-directed ADC’s median overall survival fell short of the bar set by GSK’s rival asset.
<a href="https://www.fiercebiotech.com/biotech/biontech-sets-survival-standard-hard-treat-cancer-ahead-pivotal-readout" hreflang="en">BioNTech sets survival standard in hard-to-treat cancer ahead of pivotal readout</a>
BioNTech has linked gotistobart to median overall survival of 18.5 months in relapsed lung cancer patients, adding to evidence that the anti-CTLA-4 antibody is better than the standard of care.
<a href="https://www.fiercebiotech.com/biotech/cullinan-taiho-prove-6-month-survival-benefit-phase-3-trial-advanced-lung-cancer" hreflang="en">Cullinan, Taiho showcase 6-month survival benefit in phase 3 trial for advanced lung cancer</a>
Cullinan Therapeutics and Taiho Oncology unveiled phase 3 data showing survival improvements greater than Johnson & Johnson’s Rybrevant in patients with advanced non-small cell lung cancer in the front-line setting.